188 related articles for article (PubMed ID: 20175878)
1. Crystal structure of human cystatin C stabilized against amyloid formation.
Kolodziejczyk R; Michalska K; Hernandez-Santoyo A; Wahlbom M; Grubb A; Jaskolski M
FEBS J; 2010 Apr; 277(7):1726-37. PubMed ID: 20175878
[TBL] [Abstract][Full Text] [Related]
2. Domain swapping in N-truncated human cystatin C.
Janowski R; Abrahamson M; Grubb A; Jaskolski M
J Mol Biol; 2004 Jul; 341(1):151-60. PubMed ID: 15312769
[TBL] [Abstract][Full Text] [Related]
3. Hinge-loop mutation can be used to control 3D domain swapping and amyloidogenesis of human cystatin C.
Orlikowska M; Jankowska E; Kołodziejczyk R; Jaskólski M; Szymańska A
J Struct Biol; 2011 Feb; 173(2):406-13. PubMed ID: 21074623
[TBL] [Abstract][Full Text] [Related]
4. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping.
Janowski R; Kozak M; Jankowska E; Grzonka Z; Grubb A; Abrahamson M; Jaskolski M
Nat Struct Biol; 2001 Apr; 8(4):316-20. PubMed ID: 11276250
[TBL] [Abstract][Full Text] [Related]
5. 3D domain-swapped human cystatin C with amyloidlike intermolecular beta-sheets.
Janowski R; Kozak M; Abrahamson M; Grubb A; Jaskolski M
Proteins; 2005 Nov; 61(3):570-8. PubMed ID: 16170782
[TBL] [Abstract][Full Text] [Related]
6. 3D domain swapping, protein oligomerization, and amyloid formation.
Jaskólski M
Acta Biochim Pol; 2001; 48(4):807-27. PubMed ID: 11995994
[TBL] [Abstract][Full Text] [Related]
7. Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C: use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C.
Nilsson M; Wang X; Rodziewicz-Motowidlo S; Janowski R; Lindström V; Onnerfjord P; Westermark G; Grzonka Z; Jaskolski M; Grubb A
J Biol Chem; 2004 Jun; 279(23):24236-45. PubMed ID: 15028721
[TBL] [Abstract][Full Text] [Related]
8. The role of the Val57 amino-acid residue in the hinge loop of the human cystatin C. Conformational studies of the beta2-L1-beta3 segments of wild-type human cystatin C and its mutants.
Rodziewicz-Motowidło S; Iwaszkiewicz J; Sosnowska R; Czaplewska P; Sobolewski E; Szymańska A; Stachowiak K; Liwo A
Biopolymers; 2009 May; 91(5):373-83. PubMed ID: 19137579
[TBL] [Abstract][Full Text] [Related]
9. Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: why is the L68Q variant amyloidogenic?
Rodziewicz-Motowidło S; Wahlbom M; Wang X; Lagiewka J; Janowski R; Jaskólski M; Grubb A; Grzonka Z
J Struct Biol; 2006 Apr; 154(1):68-78. PubMed ID: 16446102
[TBL] [Abstract][Full Text] [Related]
10. Exploring the 'aggregation-prone' core of human Cystatin C: A structural study.
Tsiolaki PL; Louros NN; Hamodrakas SJ; Iconomidou VA
J Struct Biol; 2015 Sep; 191(3):272-80. PubMed ID: 26235923
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for amyloidosis related to hereditary brain hemorrhage.
Abrahamson M
Scand J Clin Lab Invest Suppl; 1996; 226():47-56. PubMed ID: 8981667
[TBL] [Abstract][Full Text] [Related]
12. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation.
Sastre M; Calero M; Pawlik M; Mathews PM; Kumar A; Danilov V; Schmidt SD; Nixon RA; Frangione B; Levy E
Neurobiol Aging; 2004 Sep; 25(8):1033-43. PubMed ID: 15212828
[TBL] [Abstract][Full Text] [Related]
13. Identification of the epitope for anti-cystatin C antibody.
Sladewska A; Szymańska A; Kordalska M; Lewandowska A; Kołodziejczyk AS; Paraschiv G; Przybylski M; Czaplewska P
J Mol Recognit; 2011; 24(4):687-99. PubMed ID: 21584879
[TBL] [Abstract][Full Text] [Related]
14. Physico-chemical properties of the N-terminally truncated L68Q cystatin C found in amyloid deposits of brain haemorrhage patients.
Gerhartz B; Abrahamson M
Biol Chem; 2002 Feb; 383(2):301-5. PubMed ID: 11934268
[TBL] [Abstract][Full Text] [Related]
15. NMR structural studies of human cystatin C dimers and monomers.
Ekiel I; Abrahamson M; Fulton DB; Lindahl P; Storer AC; Levadoux W; Lafrance M; Labelle S; Pomerleau Y; Groleau D; LeSauteur L; Gehring K
J Mol Biol; 1997 Aug; 271(2):266-77. PubMed ID: 9268658
[TBL] [Abstract][Full Text] [Related]
16. Effect of antisense peptide binding on the dimerization of human cystatin C--gel electrophoresis and molecular modeling studies.
Stachowiak K; Rodziewicz-Motowidło S; Sosnowska R; Kasprzykowski F; Łankiewicz L; Grubb A; Grzonka Z
Acta Biochim Pol; 2004; 51(1):153-60. PubMed ID: 15094836
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional analysis of cystatin E reveals enzymologically relevant dimer and amyloid fibril states.
Dall E; Hollerweger JC; Dahms SO; Cui H; Häussermann K; Brandstetter H
J Biol Chem; 2018 Aug; 293(34):13151-13165. PubMed ID: 29967063
[TBL] [Abstract][Full Text] [Related]
18. The GB1 amyloid fibril: recruitment of the peripheral beta-strands of the domain swapped dimer into the polymeric interface.
Louis JM; Byeon IJ; Baxa U; Gronenborn AM
J Mol Biol; 2005 May; 348(3):687-98. PubMed ID: 15826664
[TBL] [Abstract][Full Text] [Related]
19. Two stable unfolding intermediates of the disease-causing L68Q variant of human cystatin C.
Gerhartz B; Ekiel I; Abrahamson M
Biochemistry; 1998 Dec; 37(49):17309-17. PubMed ID: 9860845
[TBL] [Abstract][Full Text] [Related]
20. Human cystatin C monomer, dimer, oligomer, and amyloid structures are related to health and disease.
Jurczak P; Groves P; Szymanska A; Rodziewicz-Motowidlo S
FEBS Lett; 2016 Dec; 590(23):4192-4201. PubMed ID: 27766618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
